TARGETING GLUTAMINE METABOLISM AS A THERAPEUTIC STRATEGY IN MYC-DRIVEN MEDULLOBLASTOMA

被引：0
|
作者：
Hanaford, Allison [1 ]
Eberhart, Charles [1 ]
Archer, Tenley [3 ]
Tamayo, Pablo [4 ]
Pomeroy, Scott [3 ]
Raabe, Eric [2 ]
机构：
[1] Johns Hopkins Sch Med, Baltimore, MD USA
[2] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
[3] Boston Childrens Hosp, Cambrdige, MA USA
[4] Eli & Edythe Broad Inst MIT & Harvard Univ, Cambrdige, MA USA
来源：
NEURO-ONCOLOGY | 2014年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MB-091
引用
收藏
页码：94 / 94
页数：1
相关论文
共 50 条
  • [31] Novel glutamine antagonist JHU-395 suppresses MYC-driven medulloblastoma growth and induces apoptosis
    Khoa Pham
    Maxwell, Micah
    Sweeney, Heather
    Alt, Jesse
    Rais, Rana
    Slusher, Barbara S.
    Eberhart, Charles G.
    Raabe, Eric H.
    CANCER RESEARCH, 2020, 80 (16)
  • [32] MYC-driven models of primitive neuroectodermal tumor are sensitive to inhibitors of glutamine metabolism.
    Ahsan, Sama F.
    Hanaford, Allison
    Weingart, Melanie
    Taylor, Isabella
    Eberhart, Charles
    Raabe, Eric
    CANCER RESEARCH, 2013, 73 (08)
  • [33] Therapeutic targeting nudix hydrolase 1 creates a MYC-driven metabolic vulnerability
    Ye, Minhui
    Fang, Yingzhe
    Chen, Lu
    Song, Zemin
    Bao, Qing
    Wang, Fei
    Huang, Hao
    Xu, Jin
    Wang, Ziwen
    Xiao, Ruijing
    Han, Meng
    Gao, Song
    Liu, Hudan
    Jiang, Baishan
    Qing, Guoliang
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [34] Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma
    Prince, Eric W.
    Balakrishnan, Ilango
    Shah, Monil
    Levy, Jean M. Mulcahy
    Griesinger, Andrea M.
    Alimova, Irina
    Harris, Peter S.
    Birks, Diane K.
    Donson, Andrew M.
    Davidson, Nathan
    Remke, Marc
    Taylor, Michael D.
    Handler, Michael H.
    Foreman, Nicholas K.
    Venkataraman, Sujatha
    Vibhakar, Rajeev
    ONCOTARGET, 2016, 7 (33) : 53881 - 53894
  • [35] CHECKPOINT KINASE 1 EXPRESSION IS AN ADVERSE PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN MYC-DRIVEN MEDULLOBLASTOMA
    Prince, Eric
    Shah, Monil
    Venkataraman, Sujatha
    Balakrishnan, Ilango
    Alimova, Irina
    Harris, Peter
    Birks, Diane
    Donson, Andrew
    Taylor, Michael
    Handler, Michael
    Foreman, Nicholas
    Vibhakar, Rajeev
    NEURO-ONCOLOGY, 2015, 17 : 24 - 24
  • [36] Targeting nucleotide synthesis in MYC-driven lymphoma
    Gemma K. Alderton
    Nature Reviews Cancer, 2014, 14 (7) : 452 - 452
  • [37] Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma
    Tateishi, Kensuke
    Iafrate, A. John
    Ho, Quan
    Curry, William T.
    Batchelor, Tracy T.
    Flaherty, Keith T.
    Onozato, Maristela L.
    Lelic, Nina
    Sundaram, Sudhandra
    Cahill, Daniel P.
    Chi, Andrew S.
    Wakimoto, Hiroaki
    CLINICAL CANCER RESEARCH, 2016, 22 (17) : 4452 - 4465
  • [38] CDK8 PROMOTES STEMNESS OF MYC-DRIVEN MEDULLOBLASTOMA
    Wang, Dong
    Veo, Bethany
    Pierce, Angela
    Venkataraman, Sujatha
    Vibhakar, Rajeev
    NEURO-ONCOLOGY, 2022, 24 : 125 - 125
  • [39] TARGETING GLUTAMINE METABOLISM IN MYC DRIVEN ATYPICAL TERATOID RHABDOID TUMORS
    Rubens, Jeffrey
    Wang, Sabrina
    Price, Antoinette
    Allen, Sariah
    Orr, Brent
    Eberhart, Charles
    Raabe, Eric
    NEURO-ONCOLOGY, 2017, 19 : 2 - 3
  • [40] New therapeutic target for MYC-driven cancers
    Hill, Rosanna
    FUTURE MEDICINAL CHEMISTRY, 2013, 5 (14) : 1603 - 1603
12345